Certain embodiments disclosed herein relate generally to replacement valves for a vascular system. In particular, the valves relate to replacement heart valves, such as for the mitral valve.
Human heart valves, which include the aortic, pulmonary, mitral and tricuspid valves, function essentially as one-way valves operating in synchronization with the pumping heart. The valves allow blood to flow downstream, but block blood from flowing upstream. Diseased heart valves exhibit impairments such as narrowing of the valve or regurgitation, which inhibit the valves' ability to control blood flow. Such impairments reduce the heart's blood-pumping efficiency and can be a debilitating and life threatening condition. For example, valve insufficiency can lead to conditions such as heart hypertrophy and dilation of the ventricle. Thus, extensive efforts have been made to develop methods and apparatus to repair or replace impaired heart valves.
Prostheses exist to correct problems associated with impaired heart valves. For example, mechanical and tissue-based heart valve prostheses can be used to replace impaired native heart valves. More recently, substantial effort has been dedicated to developing replacement heart valves, particularly tissue-based replacement heart valves that can be delivered with less trauma to the patient than through open heart surgery. Replacement valves are being designed to be delivered through minimally invasive procedures and even percutaneous procedures. Such replacement valves often include a tissue-based valve body that is connected to an expandable frame that is then delivered to the native valve's annulus.
Development of replacement heart valves that can be compacted for delivery and then controllably expanded for controlled placement, and the related delivery devices have proven to be particularly challenging.
Accordingly, there is in the need of the art for improved replacement heart valves, among other things.
In some embodiments a replacement heart valve can comprise an expandable frame, and a valve body. The expandable frame can be configured to engage a native valve annulus, wherein the frame extends longitudinally between an upstream end and a downstream end, the frame having a foreshortening portion at or adjacent the downstream end, the foreshortening portion comprising foreshortening cells that are longitudinally expanded when the frame is in a radially compacted state and longitudinally contracted when the frame is in a radially expanded state. The valve body can be coupled to the frame, the valve body coupled to the frame in the foreshortening portion in a manner so that the frame foreshortening portion can move longitudinally relative to the valve body. Upon radial compaction of the implant, the frame foreshortening portion can longitudinally expand but moves relative to the valve body so that the valve body substantially retains its longitudinal length.
According to some embodiments, a method of implanting a replacement heart valve can comprise one or more of the following steps. Advancing a replacement heart valve to a native valve annulus. Expanding a frame of the replacement heart valve from a compacted position to a first expanded configuration such that anchors on the replacement heart valve engage the native valve annulus. Reducing the diameter of the frame from the first expanded configuration to a second expanded configuration while the anchors remain engaged with the native valve annulus.
Reducing the diameter may further comprise deploying an outer ring positioned around the frame, the outer ring having a relaxed diameter less than a diameter of the frame when in the first expanded configuration. Reducing the diameter may further comprise tensioning a cord member disposed about the frame.
In some embodiments, a replacement heart valve can include a self-expandable frame, a valve body mounted to the self-expandable frame, and a tether or ring. The self-expandable frame can be configured to engage a native valve annulus when in an expanded configuration. The self-expandable frame can have a first diameter when in a relaxed, fully expanded configuration. The valve body can include a plurality of valve leaflets configured to open to allow flow in a first direction and engage one another so as to close and prevent flow in a second direction, the second direction being opposite the first direction. The tether or ring can have a second diameter when in a relaxed, fully expanded configuration, the tether or ring being fit about a portion of the self-expandable frame, where the first diameter is greater than the second diameter.
In some embodiments, a replacement heart valve can comprise an expandable frame configured to engage a native valve annulus, and a valve body mounted onto the expandable frame. The valve body can include a valve skirt configured to engage the expandable frame through a series of stitches, and a plurality of valve leaflets attached to the valve skirt. An upstream edge of each valve leaflet can be arcuate and a portion of the skirt can have an arcuate upstream edge substantially aligned with the valve leaflet upstream edges, wherein the aligned skirt and valve leaflet upstream edges can be attached to one another.
These and other features, aspects and advantages are described below with reference to the drawings, which are intended to illustrate but not to limit the invention. In the drawings, like reference characters denote corresponding features consistently throughout similar embodiments.
The associated drawings and specification discuss aspects and features of the present invention in the context of several different embodiments of heart valve implants, delivery devices and methods that are configured for use in the vasculature of a patient. Discussing these features in connection with heart valve implants employing stents provides for clarity and consistency in presenting these inventive features and concepts. However, it is to be understood that the features and concepts discussed herein can be applied to products other than heart valve implants.
As shown in
The frame 20 can be constructed with a foreshortening portion 28 so that part of the frame foreshortens as the frame is radially expanded from a collapsed or compacted configuration. In the illustrated embodiment, the foreshortening portion 28 generally corresponds with the downstream end 26. A non-foreshortening portion 30 can extend upstream from the foreshortening portion 28, and can generally correspond with the upstream 22 and transition 24 portions. The foreshortening portion 28 can include a plurality of undulating struts that form a portion of the generally oval, diamond, or other shaped cells 32 that can extend circumferentially around the frame to form the ring, or rings, of the foreshortening portion. The cells' longitudinal length increases when the frame radially compacts and the length shortens when the frame radially expands, providing the foreshortening feature of the valve frame. The foreshortening portion 28 can include foreshortening cells 32 that are longitudinally expanded when the frame 20 is in a radially compacted state and longitudinally contracted when the frame is in a radially expanded state.
The anchors 34, 36 can be positioned to be on either side of the foreshortening portion 28. This can allow the anchors to move relative to one another. In this way, with the anchors 34, 36 positioned on either side of the valve annulus of the diseased heart valve, expansion of the frame causes the opposing anchors 34, 36 to move toward one another, and can allow the replacement heart valve to be secured to the valve annulus through the anchors grasping opposite sides of the annulus. The valve implant 10 is shown with the downstream end 26, or the downstream-most portion of the anchor 34, coupled to a loading device configured to form and load the valve implant 10 onto a delivery device.
In some instances, there is a potential for a patient, having received a replacement heart valve, to develop an enlarged valve annulus. This may be due to radially outward force exerted on the annulus by self-expanding of the replacement heart valve over an extended period of time, among other features. An enlarged mitral valve annulus can impair valve function and result in left atrial and ventricular enlargement and significant mitral regurgitation. Accordingly, there is a need in the art for apparatus and methods to mitigate the risk of valve frame induced enlargement of the annulus.
In some embodiments, a heart valve implant 10′ can be expanded to a first installed diameter D1 (
The embodiment illustrated in
With continued reference to
In some embodiments, only some of the eyelets 38 protrude outward from the frame 20′. More particularly, the eyelets 38 can protrude outward where the tether 40 transitions from extending circumferentially around the frame 20′ to extending in a longitudinal direction, such as toward a delivery device or system. In some embodiments, the eyelets 38 can lie on the same plane as the frame struts so as not to protrude radially inward or outward from the frame. For example, the eyelet 38 can be positioned within the same diametral geometry as the frame. In some embodiments, the eyelets 38 are fully enclosed loops that can be circular (
The number of eyelets 38 can vary based upon the characteristics of the frame, the tether, and the intended deployment of the valve implant. For example, a larger diameter frame can include a greater number of eyelets to securedly affix the tether to the frame and prevent movement, or creep, of the tether subsequent to the deployment of the valve frame.
The eyelets 38 can be formed, or fabricated, as an integral part of the frame 20′ and machined, cut, formed, stamped, or the like, out of the same tube material as the remaining portions of the frame. In some embodiments, the eyelets 38 can be separately fabricated and coupled to the frame 20′ by various manufacturing methods, e.g. laser welding, brazing, adhesives, or the like.
With continued reference to
Preferably, the tether 40 and eyelets 38 are arranged so that the tether extends about the outer diameter of the frame 20′. In some embodiments, the tether can wrap around the frame for the full circumference, or more than a full circumference, e.g. 1¼, 1½, or the like, such that tension applied to the first and second ends of the tether reduces or limits the circumference of the frame. In some embodiments, the tether can wrap around a portion of the circumference, e.g. ½, ⅔, ¾, or the like.
A method of using the tether 40 will now be described. The tether 40 can be coupled to the compacted valve implant 10′ prior to insertion and deployment of the same within the patient. The tether 40 can be wrapped around the frame 20′, such as passing through eyelets 38 disposed about the foreshortening portion 28′ or other portions of the frame 20′. The first 42 and second 44 ends of the tether 40 can extend proximally from a pair of longitudinal transition eyelets that preferably are generally diametrically opposed from one another on the frame. In some embodiments, the two longitudinal transition eyelets can be disposed at positions that are other than generally 180 degrees apart from one another.
The valve implant 10′ can then be suitably positioned at the mitral valve annulus and radially expanded so that the anchors 34′, 36′ grasp the annulus on both the upstream and downstream sides of the annulus. The frame can be self-expanding, e.g. fabricated with shape memory material, or can be balloon expanded. The frame 20′ can expand to a first diameter to ensure suitable engagement, or grasping, of the anchors onto, or with, the mitral valve annulus (
Once the valve implant 10′ has been expanded to the first diameter D1, the tether 40 can be tensioned by pulling, or retracting, the first end 42 and/or the second end 44 of the tether 40, such as in the proximal direction. The tensioned tether can secure the frame to prevent further expansion and/or reduce the diameter of the frame. The tension can be sufficient to create an inward radial force on the frame to overcome radial outward self-expansion force of the frame. The greater inward radial force can reduce the diameter of the frame. The first end 42 and the second end 44 can be pulled in tension until the diameter of the frame achieves a suitable reduced second diameter D2. The tensioned tether 40 can reduce the radial force exerted on the valve annulus and reduce the risk of an enlarged mitral valve annulus over an extended period of time. Also, the diameter can preferable be dialed in to the desired effective size for the valve implant 10′.
In some embodiments, the tether 40 can be secured in the tensioned position to maintain the frame 20′ in the reduced diameter position. The tether 40 can also be secured around the foreshortening portion of a self-expanding shape memory frame. Such securement can be by any method and/or apparatus, such as knot-tying, melting, or crimping a securement structure about the tether and/or an eyelet, and the like. In some embodiments, the tether can be bio-absorbable, as described above. The tether may also be used in conjunction with a balloon expanded frame. A bio-absorbable tether can reduce the frame diameter to achieve elastic deformation and can be temporarily secured to hold the frame diameter until the tether is absorbed into the body. In some embodiments, the tether is not required to be secured and can be removed from the body after the frame diameter is reduced.
In another embodiment, the second end 44 of the tether 40 is tied or otherwise bonded to the valve frame 20′. Tether adjustment can be made by pulling on the first end 42 of the tether 40.
In another embodiment, the tether 40 may include a plurality of one-way stop members that allow a clinician to pull and tighten the tether but prevent the tether from loosening once tightened. The one-way stop members can comprise a ratcheting mechanism. The one-way stop members can each have a sloping forward surface and a perpendicular back stop surface. In other words, the one-way stop members can have a tapered surface that flares out to a back wall. As the clinician pulls on the tether, the sloped or tapered surface of a member can be pulled through the corresponding eyelet. Once the stop member is pulled through the eyelet, the back wall or stop surface can abut the eyelet. If the clinician were to release tension on the tether, the stop surface would not be able to pass back through the eyelet, and the tether thus would not loosen. As such, a clinician can reduce the diameter/circumference of a self-expanding or other type of valve frame after deployment by pulling the tether sufficient to obtain a desired maximum circumference. The one-way stop members will then prevent loosening of the tether, and thus the tether will constrain the valve frame to that maximum desired circumference. The remaining portion of the tether can then be cut and removed.
The one-way stop members can have a cross-sectional shape that is triangular, wedge shaped, bullet shaped, a half circle, arrow shaped, etc.
In still another embodiment, a ball-shaped stop is disposed at each of the tether first 42 and second 44 ends. The distance along the tether between the first and second end stops is selected as the maximum desired valve frame circumference. The tether 40 preferably is threaded through the eyelets 38 as discussed above. However the stops are sized and shaped so that they cannot be pulled through the eyelets. When the valve frame is compacted prior to deployment, the tether fits relatively loose around the frame. Upon deployment the valve frame is allowed to expand until the stops engage corresponding eyelets, defining a maximum expansion size. Of course it is to be understood that the tether stops could be constructed in various shapes and sizes other than the ball-shaped stops described.
In some embodiments, a self-expanding valve frame is configured to have a relaxed diameter and circumference that is greater than ultimately desired. As such, the valve frame is biased to expand to that size. However as the frame expands, eventually the first and second stops will each abut corresponding eyelets and thus prevent further expansion beyond the desired diameter and circumference as defined by the tether. Since the self expanding frame is biased to expand further, it will resist other forces within the heart that would tend to compress and/or otherwise deform the valve frame.
In yet another embodiment, the tether comprises a loop that is flexible, but resists stretching. The tether preferably is threaded through the eyelets. When the valve frame is compacted prior to deployment, the tether fits relatively loose around the frame. Upon deployment the valve frame is allowed to expand until the maximum diameter of the tether loop is reached, defining a maximum expansion size.
With reference now to the illustrated embodiment of
The heart valve implant 10″ can be similar to the embodiments described above. The frame 20″ can comprise a self-expanding material, e.g. a shape memory material, Nitinol, or the like, or can be balloon-expandable. Preferably, an outer ring 46 is disposed about the frame 20″, such as about the foreshortening portion 28″ of the frame. In the illustrated embodiment, the outer ring 46 is formed separately from the valve frame 20″. The outer ring 46 can be configured to reduce the over-expanded, or enlarged, first diameter D1 of the frame (
The outer ring 46 can take many forms. For example, the outer ring can form a pattern of undulating struts, a sinusoidal, or wave configuration. As illustrated, the outer ring 46 can have two rows of undulating struts to form a series of cells of various shapes. Thus, the outer ring can be a foreshortening ring or cell, comprising a row of connected ovals, diamonds, circles, or similar geometric shapes. The shapes can be coupled adjacent one another, similar to the rows establishing the foreshortening portion of the frame, described above. In some embodiments, the outer ring can comprise more than one row of similar geometric shapes. The ovals can comprise a plurality of struts, all positioned at non-zero angles relative to the longitudinal axis, with no longitudinal struts. In some embodiments, the outer ring can be a non-foreshortening ring and can comprise longitudinal struts.
The outer ring 46 can be a self-expanding ring configured to expand or compact the frame to the second diameter D2. In some embodiments, the outer ring 46 can be a shape memory material. In some embodiments, a shape memory outer ring 46 can expand or contract to the second diameter upon reaching body temperature, or some other set temperature. The outer ring can be manufactured in a similar manner as the implant frame.
The outer ring 46 can have a relaxed expanded inner diameter that is the same as or larger than the relaxed expanded outer diameter of the implant frame 20″. In some embodiments, the outer ring's relaxed expanded inner diameter can be less than the frame's relaxed expanded outer diameter, and in some such embodiments the outer ring can form an interference fit with the frame. In further embodiments, the outer ring 46 can be physically coupled to the frame 20″ by any conventional manufacturing method, e.g. laser welding, brazing, adhesives, fasteners, cables, or the like. The outer ring 46 can be coupled to the frame at one or more locations about the frame, such as coupling locations generally equally spaced about the frame. The couplings can be sufficient to prevent longitudinal migration of the outer ring about the frame. The outer ring 46 can be coupled generally in any longitudinal position along frame, including along the foreshortening portion 28″ of the valve frame 20″. In some embodiments, the outer ring can be positioned in substantially the middle longitudinal location or mid-point of the valve frame foreshortening portion.
In some embodiments, the outer ring 46 can be coupled to a power source 48, e.g. an RF power source, or the like. The power source 48 can be configured to selectively increase the temperature of a shape memory outer ring 46 to the set temperature. This can allow the device to expeditiously achieve the reduced second diameter D2, rather than to rely on the environment to heat the device to the desired set temperature.
In some embodiments, the power source 48 and the power source coupling 50 can be removable, and can be removed from the valve implant 10″ after the frame 20″ has reached the desired diameter. In some embodiments, the outer ring can have no power source coupled to the ring, and the outer ring may be configured to assume the second diameter at a slower rate than the valve frame, as the temperature of the ring approaches the heat treat set temperature at a slower rate than with the assistance of the power source.
A method of using the outer ring 46 according to an embodiment will now be described. The outer ring 46 can be coupled to or arranged over the valve frame 20″ prior to insertion of the valve implant 10″ into the body for implant deployment. The outer ring 46 can generally be compacted to a smaller diameter about the radially compacted implant 10″. The outer ring 46 may be held by a retention sleeve or delivery device, or may be frozen in place. In some embodiments, the outer ring can be maintained at a temperature below normal body temperature or some other set temperature to prevent premature expansion. The outer ring can be maintained at a lower temperature by, for example, a fluid environment within the delivery catheter until a suitable time prior to the final deployment sequence.
The valve 10″ can be released from the delivery device and the foreshortening portion 28″ positioned adjacent the mitral valve annulus. The valve frame 20″ can self-expand or be balloon expanded to the enlarged first diameter D1 and the anchors 34″, 36″ can engage the valve annulus on opposing sides of the annulus. The power supply 48 can then provide energy to increase the temperature of the outer ring 46. For example, RF energy can be delivered via the power source coupled to the outer ring. The increase in temperature can change the outer ring shape as the ring recovers to the heat treated set shape memory of the reduced second diameter D2. The radially inward force of the outer ring 46 is greater than the radially outward force of the frame 20″ and the frame diameter correspondingly reduces to the reduced second diameter D2 and/or is prevented from further radial expansion due to the radially-inward force applied by the outer ring 46. The reduced diameter preferably does not detrimentally affect anchor engagement as the upstream to downstream anchor tip distance can be minimally increased as the frame diameter reduces to the second diameter.
It will be understood that though the frame is generally described as moving from a first diameter D1 to a second diameter D2, the frame may expand to the desired diameter without an intermediate step. The outer ring, tether, or other devices can be used to limit or control the expansion of the frame.
In another embodiment, the valve implant can have a self-expanding frame heat treated to self-expand to the second reduced diameter and yet be balloon expanded beyond the reduced second diameter to the enlarged first diameter. The frame upstream and downstream anchors can engage the mitral valve annulus to grasp the opposing sides of the annulus in the enlarged radius configuration. The balloon can be deflated after suitable anchor engagement is verified, e.g. by observation methods, or the like. The frame can then return to the heat treated reduced second diameter without the balloon outward radial force applied to the frame inner diameter. This can be done in many ways, including heating through body temperature or coupling the frame to a power source similar to that described above.
Moving now to
With continued reference to
A method of using the reverse foreshortening anchors 52, 54 will now be described according to one embodiment. The reverse foreshortening anchors 52, 54 are generally at their closest tip to tip relative longitudinal position when the frame is in the compacted configuration. The implant 10 is delivered into the vasculature and positioned and deployed at the mitral valve native annulus. The implant frame 20 can be expanded to the enlarged first diameter and then reduced in diameter to the reduced second diameter. In some embodiments, the reduction in diameter can cause the longitudinal distance between foreshortening anchor tips to increase. In some embodiments, the reverse foreshortening anchors can be assembled in conjunction with the normal foreshortening anchors, but their anchor tips will move closer toward one another when the frame radius decreases to the reduced second diameter. In some embodiments, the reverse foreshortening anchors can be positioned at every other circumferentially spaced expanded leg position. Thus, as the normal foreshortening anchors decrease engagement, the second foreshortening anchors can increase engagement by having the reverse foreshortening movement of the anchors reduce the tip to tip gap toward one anther.
Turning now to
As has been mentioned, the replacement heart valve 10 of
With continued reference to
In some embodiments, as illustrated at
With reference to the illustrated embodiment of
The upstream end 37′″ of the valve skirt 33′″ can also vary from the upstream end 22′″ of the frame 20′″. In particular, the valve skirt can have varying geometry that deviates from the upstream end. The upstream geometry 37 of the valve skirt 33 can be tapered, as shown in
Referring now to
The different embodiments of valve skirt pieces shown in
The valve skirt pieces 80 of
The skirt pieces 80 can also include a second straight tapered edge portion 88, or transition edge, shaped to accommodate the change in diameter of the frame transition portion when attached to the second tapered edge 88 of an adjoining skirt piece 80. In some embodiments, the second tapered edge 88 can extend at a different angle than the first tapered edge 86. In some embodiments, the second tapered edge 88 can have the same angle as the first tapered edge 86. A downstream edge 90 of each skirt piece is shaped to accommodate the larger diameter of the expanded downstream frame portion when attached to the downstream edge 90 of an adjoining skirt piece 80. In the illustrated embodiment, the connecting edge 82 is made up of the stitched together transition edges 88 and downstream edges 90 of adjoining skirt pieces 80.
Referring primarily to
In the illustrated embodiments, the stitches adjoining skirt edges is positioned generally in line with longitudinal struts of the frame, and are stitched to the frame as shown in
In some embodiments, the angle or radius of the arcuate edge can vary, providing different sized spaced gap areas between the valve skirt pieces in the upstream portion of the frame. The spaced gap area between the valve skirt pieces advantageously provides a flow path for blood to pass between the inner surface and the outer surface of the upstream portion of the valve implant. The spaced gap establishes reduced valve body surface coverage on the frame, which reduces the frame's impact on blood flow about the implant upstream end. The upstream portion of the valve implant is generally positioned in the left atrium after complete deployment, and the flow path areas reduce any flow impact or flow restrictions in the left atrium attributable to the replacement valve implant. The spaced gap also reduces the valve body mass, or volume, in the frame upstream portion. The reduced mass, or volume, reduces the compacted storage volume required to store the replacement heart valve in a reduced diameter tube-like body.
With reference to
With reference to
The valve leaflets 56 are shown stitched to the valve skirt 33 between the adjacent skirt piece ends at the skirt longitudinal stitches 60. The commissural tabs 58 of two adjacent leaflet pieces extend through the longitudinal stitch 60. The two commissural tabs 58 are generally positioned in line with the longitudinal strut 62 and adjacent the foreshortening portion of the frame 20. The longitudinal strut 62 is located between the two radially outwardly protruding commissural tabs, as shown in
Turning now to
The replacement heart valve illustrates various additional features, one or more of which may be incorporated into a respective replacement heart valve. Similar to the other replacement heart valves discussed herein, the replacement heart valve in
In some embodiments, a support band 64 may be placed or positioned around or within the valve frame 20″″ at the proximal end 22″″. The support band 64 can be used to reinforce and/or constrain the valve frame at its proximal end 22″″. The support band 64 can help to control the expansion of the valve frame from the compacted to the expanded state and/or limit further expansion as previously discussed. The support band 64 can also be used to reduce the amount of motion that occurs at the proximal end 22″″ after the replacement heart valve 10″″ has been implanted within the mitral heart valve or other location.
In some embodiments, the support band 64 may comprise a fabric, polyester band. The support band may comprise a no-stretch or limited stretch material. Preferably the support band is not made of an elastic material or a material known to have high elasticity.
The support band 64 can be connected to the valve frame 20″″ with a plurality of stitches, loops, knots, or other types of connections. In some embodiments the support band 64 can sandwich the valve frame 20″″ between two sides or layers of the support band. Preferably, the support band is a single layer positioned within the valve frame and attached to the valve frame with a plurality of stitches around one or more of the longitudinal and/or undulating struts of the valve frame.
In some embodiments, a replacement heart valve 10″″ may include one or more flaps or gills 66 as illustrated in
In the illustrated embodiment, a V-shaped cut 66 has been made in the valve skirt 33″″. The flap 66 is positioned within the valve frame 20″″ and as shown, can be considered as attached at the top or proximal end of the hole and hanging down into the valve. The flaps 66 can be attached at one or more sides of the hole. The flap 66 can include additional material so that the flap is larger than the hole made by the cut and can cover or close the entire hole. This additional material can also prevent the flap from being forced through the hole and effectively block or plug the hole.
The flaps or gills 66 in the valve skirt 33″″ can provide additional benefits. For example, one or more flaps 66 along the valve skirt can allow blood to flow around the valve skirt. The flaps 66 can also open and close with the flow of blood and the beating of the heart. For example, the flap 66 can be open during diastole and close during systole. The flaps 66 can reduce pressure on the valve skirt, while the primary flow of blood still flows through the center of the replacement heart valve and through the leaflets. In some embodiments, the flap 66 can be closed during diastole and open during systole. Further, in some embodiments, the flaps can be configured to allow some leakage, or a minimal amount of flow through when they are otherwise closed.
In some embodiments, the valve skirt includes the holes without the flaps. For example, the skirt can have one or more horizontal slits or slots. The slits can be positioned in the diamond or cell area of the frame, as one example. The valve skirt can also be a porous material. The valve skirt may or may not have a scalloped edge in this configuration. In some embodiments without a scalloped edge, or at least with some region of the skirt being upstream of the leaflet upstream edge, holes are formed only in the region of the skirt upstream of the leaflet upstream edge.
Another feature which can be included on a replacement heart valve 10″″ is a layered multi-piece valve skirt 33″″. The valve skirt 33″″ can have multiple pieces of material that overlap one another 68, 70, 72. This can allow blood to flow through the valve skirt 33″″ on the sides of the replacement heart valve 10″″ and between the layers 68, 70, 72 of valve skirt material. As shown, the proximal section of the valve skirt can be made up of one layer of material 72. A middle section of material 70 can be layered on top of the proximal section 72. The distal section 68 can then be layered over the end of the middle section 70. Similar to the flaps 66, blood can flow through the layers of valve skirt fabric. The layers can also be loose inside of the valve frame such that they act as a valve to open and close similar to the flaps discussed above, as shown in
The multi-piece valve skirt can be made of one or more materials. For example, the entire skirt, one or more layer, or one or more portions of one or more layers can be made of fabric, or of tissue, such as porcine tissue. In some embodiments, one or more layer can be a porous material, such as a porous fabric. The porous material can be configured to remain porous or to close up over time. For example, one layer such as either the layer 68, or the layer 72 can be made of fabric while the other two layers are made of tissue.
The multi-piece valve skirt can be sewn together at one or more locations. The stitch can be a discontinuous stitch that extends around the circumference and/or longitudinally. The gaps between the stitches and the overlapping material can be configured and sized to prevent prolapse. The multi-piece valve skirt can form one or more circular flaps as shown in
The overlapping multi-piece valve skirt, the scalloped edge, and the flaps can function as mini-leaflets to vent and/or allow flow through the replacement heart valve. The overlapping multi-piece valve skirt, the scalloped edge, and the flaps can also be beneficial during the implantation process to allow flow through the replacement heart valve prior to complete implantation of the device. These features and the related features discussed above can allow blood to flow other than directly through the valve. For example, a washout to the left atrium, a pop-off valve, a pressure relief valve, etc. can be provided. The holes, slits, flaps, overlapping, etc. can be configured to change over time, such that more flow is allowed through initially, but overtime the flow is diminished through tissue build-up or other effects of having the replacement valve in the body. In addition, holes, vents, slits, flaps, etc. can also be used to reduce pressure on the valve skirt when moving when the compressed and expanded positions.
Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. For example, the tether and eyelets of
Similarly, this method of disclosure, is not to be interpreted as reflecting an intention that any claim require more features than are expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following the Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment.
This application is a continuation of U.S. application Ser. No. 16/227,401, filed Dec. 20, 2018, which is a divisional of U.S. application Ser. No. 15/011,247, filed Jan. 29, 2016, now U.S. Pat. No. 10,166,097, which is a continuation of U.S. application Ser. No. 13/755,406, filed Jan. 31, 2013, now U.S. Pat. No. 9,480,560, which is a continuation of U.S. application Ser. No. 13/403,929, filed Feb. 23, 2012, now U.S. Pat. No. 9,730,790, which claims priority to U.S. Provisional Appl. No. 61/445,963, filed Feb. 23, 2011. This application is also related to U.S. application Ser. No. 12/569,856, filed Sep. 29, 2009, Ser. No. 12/761,349, filed Apr. 15, 2010, Ser. No. 13/165,721, filed Jun. 21, 2011, and Ser. No. 13/244,080, filed Sep. 23, 2011. These related applications provide context for the present disclosure, and in some instances the present disclosure describes embodiments and principles that build on the previous applications. All of the above applications are hereby incorporated herein by reference in their entirety and are to be considered a part of this specification.
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3739402 | Cooley et al. | Jun 1973 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4079468 | Liotta et al. | Mar 1978 | A |
4204283 | Bellhouse et al. | May 1980 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4265694 | Boretos et al. | May 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4340977 | Brownlee et al. | Jul 1982 | A |
4470157 | Love | Sep 1984 | A |
4477930 | Totten et al. | Oct 1984 | A |
4490859 | Black et al. | Jan 1985 | A |
4553545 | Maass et al. | Nov 1985 | A |
4655771 | Wallsten | Apr 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4865600 | Carpentier et al. | Sep 1989 | A |
4994077 | Dobben | Feb 1991 | A |
5197978 | Hess | Mar 1993 | A |
5326371 | Love et al. | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5397355 | Marin et al. | Mar 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5415667 | Frater | May 1995 | A |
5439446 | Barry | Aug 1995 | A |
5474563 | Myler et al. | Dec 1995 | A |
5509930 | Love | Apr 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5575818 | Pinchuk | Nov 1996 | A |
5607444 | Lam | Mar 1997 | A |
5607469 | Frey | Mar 1997 | A |
5669919 | Sanders et al. | Sep 1997 | A |
5693061 | Pierce et al. | Dec 1997 | A |
5697382 | Love et al. | Dec 1997 | A |
D390957 | Fontaine | Feb 1998 | S |
5713952 | Vanney et al. | Feb 1998 | A |
5725519 | Penner et al. | Mar 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5807398 | Shaknovich | Sep 1998 | A |
5810873 | Morales | Sep 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5853162 | Zurke | Dec 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5868777 | Lam | Feb 1999 | A |
5868782 | Frantzen | Feb 1999 | A |
5876437 | Vanney et al. | Mar 1999 | A |
5879381 | Moriuchi et al. | Mar 1999 | A |
5902334 | Dwyer et al. | May 1999 | A |
5935108 | Katoh et al. | Aug 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5992000 | Humphrey et al. | Nov 1999 | A |
6004328 | Solar | Dec 1999 | A |
6015431 | Thornton et al. | Jan 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6053940 | Wijay | Apr 2000 | A |
6086612 | Jansen | Jul 2000 | A |
6113612 | Swanson et al. | Sep 2000 | A |
6113631 | Jansen | Sep 2000 | A |
6132458 | Staehle et al. | Oct 2000 | A |
6152937 | Peterson et al. | Nov 2000 | A |
6159237 | Alt et al. | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6168616 | Brown, III | Jan 2001 | B1 |
6251093 | Valley et al. | Jun 2001 | B1 |
6280466 | Kugler et al. | Aug 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6336938 | Kavteladze et al. | Jan 2002 | B1 |
6352543 | Cole | Mar 2002 | B1 |
6358277 | Duran | Mar 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | Matteo et al. | Aug 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6475237 | Drasler et al. | Nov 2002 | B2 |
6482228 | Norred | Nov 2002 | B1 |
6511491 | Grudem et al. | Jan 2003 | B2 |
6517550 | Konya et al. | Feb 2003 | B1 |
6517573 | Pollock et al. | Feb 2003 | B1 |
6527800 | McGuckin, Jr. et al. | Mar 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6602281 | Klein | Aug 2003 | B1 |
6610088 | Gabbay | Aug 2003 | B1 |
6641606 | Ouriel et al. | Nov 2003 | B2 |
6652578 | Bailey et al. | Nov 2003 | B2 |
D484979 | Fontaine | Jan 2004 | S |
6676698 | McGuckin, Jr. et al. | Jan 2004 | B2 |
6682537 | Ouriel et al. | Jan 2004 | B2 |
6695878 | McGuckin, Jr. et al. | Feb 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6723123 | Kazatchkov et al. | Apr 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6733523 | Shaolian et al. | May 2004 | B2 |
6764505 | Hossainy et al. | Jul 2004 | B1 |
6767362 | Schreck | Jul 2004 | B2 |
6780200 | Jansen | Aug 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6858034 | Hijlkema et al. | Feb 2005 | B1 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908477 | McGuckin, Jr. et al. | Jun 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
6926732 | Derus et al. | Aug 2005 | B2 |
6929660 | Ainsworth et al. | Aug 2005 | B1 |
6936058 | Forde et al. | Aug 2005 | B2 |
6979350 | Moll et al. | Dec 2005 | B2 |
7018401 | Hyodoh et al. | Mar 2006 | B1 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7025780 | Gabbay | Apr 2006 | B2 |
7044962 | Elliott | May 2006 | B2 |
7044966 | Svanidze et al. | May 2006 | B2 |
7087088 | Berg et al. | Aug 2006 | B2 |
7147660 | Chobotov et al. | Dec 2006 | B2 |
7147661 | Chobotov et al. | Dec 2006 | B2 |
7153322 | Alt | Dec 2006 | B2 |
7186265 | Sharkawy et al. | Mar 2007 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
D553747 | Fliedner | Oct 2007 | S |
7276078 | Spenser et al. | Oct 2007 | B2 |
7276084 | Yang et al. | Oct 2007 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7445631 | Salahieh et al. | Nov 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7524330 | Berreklouw | Apr 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7608114 | Levine et al. | Oct 2009 | B2 |
7615072 | Rust et al. | Nov 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7628805 | Spenser et al. | Dec 2009 | B2 |
7632298 | Hijlkema et al. | Dec 2009 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7753949 | Lamphere et al. | Jul 2010 | B2 |
D622387 | Igaki | Aug 2010 | S |
D622388 | Igaki | Aug 2010 | S |
7771463 | Ton et al. | Aug 2010 | B2 |
7771472 | Hendricksen et al. | Aug 2010 | B2 |
7785360 | Freitag | Aug 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7806917 | Xiao | Oct 2010 | B2 |
7806919 | Bloom et al. | Oct 2010 | B2 |
7815589 | Meade et al. | Oct 2010 | B2 |
7815673 | Bloom et al. | Oct 2010 | B2 |
7824443 | Salahieh et al. | Nov 2010 | B2 |
7846203 | Cribier | Dec 2010 | B2 |
7871435 | Carpentier et al. | Jan 2011 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
D635261 | Rossi | Mar 2011 | S |
D635262 | Rossi | Mar 2011 | S |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7947075 | Goetz et al. | May 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7972378 | Tabor et al. | Jul 2011 | B2 |
7981151 | Rowe | Jul 2011 | B2 |
7993392 | Righini et al. | Aug 2011 | B2 |
7993394 | Hariton et al. | Aug 2011 | B2 |
8016870 | Chew et al. | Sep 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8070800 | Lock et al. | Dec 2011 | B2 |
8070802 | Lamphere et al. | Dec 2011 | B2 |
8075615 | Eberhardt et al. | Dec 2011 | B2 |
8080054 | Rowe | Dec 2011 | B2 |
8092520 | Quadri | Jan 2012 | B2 |
8109996 | Stacchino et al. | Feb 2012 | B2 |
8136218 | Millwee et al. | Mar 2012 | B2 |
8137398 | Tuval et al. | Mar 2012 | B2 |
8157852 | Bloom et al. | Apr 2012 | B2 |
8167926 | Hartley et al. | May 2012 | B2 |
8167934 | Styrc et al. | May 2012 | B2 |
8177799 | Orban, III | May 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8182530 | Huber | May 2012 | B2 |
8216261 | Solem | Jul 2012 | B2 |
8216301 | Bonhoeffer et al. | Jul 2012 | B2 |
8219229 | Cao et al. | Jul 2012 | B2 |
8220121 | Hendriksen et al. | Jul 2012 | B2 |
8221482 | Cottone et al. | Jul 2012 | B2 |
8221493 | Boyle et al. | Jul 2012 | B2 |
8226710 | Nguyen et al. | Jul 2012 | B2 |
D665079 | Zago | Aug 2012 | S |
D665080 | Zago | Aug 2012 | S |
8236045 | Benichou et al. | Aug 2012 | B2 |
8246675 | Zegdi | Aug 2012 | B2 |
8246678 | Salahieh et al. | Aug 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8252052 | Salahieh et al. | Aug 2012 | B2 |
8287584 | Salahieh et al. | Oct 2012 | B2 |
8303653 | Bonhoeffer et al. | Nov 2012 | B2 |
8313525 | Tuval et al. | Nov 2012 | B2 |
8317854 | Ryan et al. | Nov 2012 | B1 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8337541 | Quadri et al. | Dec 2012 | B2 |
8353953 | Giannetti et al. | Jan 2013 | B2 |
8361137 | Perouse | Jan 2013 | B2 |
8361537 | Shanley | Jan 2013 | B2 |
8398708 | Meiri et al. | Mar 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8414645 | Dwork et al. | Apr 2013 | B2 |
8444689 | Zhang | May 2013 | B2 |
8449466 | Duhay et al. | May 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8449625 | Campbell et al. | May 2013 | B2 |
8454685 | Hariton et al. | Jun 2013 | B2 |
8460368 | Taylor et al. | Jun 2013 | B2 |
8470023 | Eidenschink et al. | Jun 2013 | B2 |
8475521 | Suri et al. | Jul 2013 | B2 |
8475523 | Duffy | Jul 2013 | B2 |
8479380 | Malewicz et al. | Jul 2013 | B2 |
8486137 | Suri et al. | Jul 2013 | B2 |
8491650 | Wiemeyer et al. | Jul 2013 | B2 |
8500798 | Rowe et al. | Aug 2013 | B2 |
8511244 | Holecek et al. | Aug 2013 | B2 |
8512401 | Murray, III et al. | Aug 2013 | B2 |
8518106 | Duffy et al. | Aug 2013 | B2 |
8535368 | Headley, Jr. et al. | Sep 2013 | B2 |
8562663 | Mearns et al. | Oct 2013 | B2 |
8579963 | Tabor | Nov 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8579965 | Bonhoeffer et al. | Nov 2013 | B2 |
8584849 | McCaffrey | Nov 2013 | B2 |
8585749 | Shelso | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8585756 | Bonhoeffer et al. | Nov 2013 | B2 |
8591570 | Revuelta et al. | Nov 2013 | B2 |
8597348 | Rowe et al. | Dec 2013 | B2 |
8617236 | Paul et al. | Dec 2013 | B2 |
8640521 | Righini et al. | Feb 2014 | B2 |
8647381 | Essinger et al. | Feb 2014 | B2 |
8652145 | Maimon et al. | Feb 2014 | B2 |
8652201 | Oberti et al. | Feb 2014 | B2 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8668733 | Haug et al. | Mar 2014 | B2 |
8672992 | Orr | Mar 2014 | B2 |
8673000 | Tabor et al. | Mar 2014 | B2 |
8679174 | Ottma et al. | Mar 2014 | B2 |
8679404 | Liburd et al. | Mar 2014 | B2 |
8685086 | Navia et al. | Apr 2014 | B2 |
8707957 | Callister et al. | Apr 2014 | B2 |
8721707 | Boucher et al. | May 2014 | B2 |
8721708 | Seguin et al. | May 2014 | B2 |
8721714 | Kelley | May 2014 | B2 |
8728154 | Alkhatib | May 2014 | B2 |
8728155 | Montorfano et al. | May 2014 | B2 |
8740974 | Lambrecht et al. | Jun 2014 | B2 |
8740976 | Tran et al. | Jun 2014 | B2 |
8747458 | Tuval et al. | Jun 2014 | B2 |
8747459 | Nguyen et al. | Jun 2014 | B2 |
8747460 | Tuval et al. | Jun 2014 | B2 |
8753384 | Leanna | Jun 2014 | B2 |
8758432 | Solem | Jun 2014 | B2 |
8764814 | Solem | Jul 2014 | B2 |
8764818 | Gregg | Jul 2014 | B2 |
8771344 | Tran et al. | Jul 2014 | B2 |
8771345 | Tuval et al. | Jul 2014 | B2 |
8771346 | Tuval et al. | Jul 2014 | B2 |
8778020 | Gregg et al. | Jul 2014 | B2 |
8784478 | Tuval et al. | Jul 2014 | B2 |
8784481 | Alkhatib et al. | Jul 2014 | B2 |
8790387 | Nguyen et al. | Jul 2014 | B2 |
8795356 | Quadri et al. | Aug 2014 | B2 |
8795357 | Yohanan et al. | Aug 2014 | B2 |
8828078 | Salahieh et al. | Sep 2014 | B2 |
8828079 | Thielen et al. | Sep 2014 | B2 |
8834564 | Tuval et al. | Sep 2014 | B2 |
8845718 | Tuval et al. | Sep 2014 | B2 |
8852267 | Cattaneo | Oct 2014 | B2 |
8870947 | Shaw | Oct 2014 | B2 |
8870948 | Erzberger et al. | Oct 2014 | B1 |
8876883 | Rust | Nov 2014 | B2 |
8876893 | Dwork et al. | Nov 2014 | B2 |
8876895 | Tuval et al. | Nov 2014 | B2 |
8911455 | Quadri et al. | Dec 2014 | B2 |
8926693 | Duffy et al. | Jan 2015 | B2 |
8945209 | Bonyuet et al. | Feb 2015 | B2 |
8951299 | Paul et al. | Feb 2015 | B2 |
8961583 | Hojeibane et al. | Feb 2015 | B2 |
8961593 | Bonhoeffer et al. | Feb 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8974524 | Yeung et al. | Mar 2015 | B2 |
8979922 | Jayasinghe et al. | Mar 2015 | B2 |
8986372 | Murry, III et al. | Mar 2015 | B2 |
8992608 | Haug et al. | Mar 2015 | B2 |
8998979 | Seguin et al. | Apr 2015 | B2 |
8998980 | Shipley et al. | Apr 2015 | B2 |
9005273 | Salahieh et al. | Apr 2015 | B2 |
9011521 | Haug et al. | Apr 2015 | B2 |
9011523 | Seguin | Apr 2015 | B2 |
9011524 | Eberhardt | Apr 2015 | B2 |
9028545 | Taylor | May 2015 | B2 |
9029418 | Dove et al. | May 2015 | B2 |
9034032 | McLean et al. | May 2015 | B2 |
9034033 | McLean et al. | May 2015 | B2 |
9039757 | McLean et al. | May 2015 | B2 |
9055937 | Rowe et al. | Jun 2015 | B2 |
9078749 | Lutter et al. | Jul 2015 | B2 |
9078751 | Naor | Jul 2015 | B2 |
9084676 | Chau et al. | Jul 2015 | B2 |
9125738 | Figulla et al. | Sep 2015 | B2 |
9138312 | Tuval et al. | Sep 2015 | B2 |
9161834 | Taylor et al. | Oct 2015 | B2 |
9480560 | Quadri et al. | Nov 2016 | B2 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010047180 | Grudem et al. | Nov 2001 | A1 |
20010047200 | White et al. | Nov 2001 | A1 |
20020016623 | Kula et al. | Feb 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020045929 | Diaz | Apr 2002 | A1 |
20020052644 | Shaolian et al. | May 2002 | A1 |
20020055772 | McGuckin et al. | May 2002 | A1 |
20020111619 | Keast et al. | Aug 2002 | A1 |
20020183827 | Derus et al. | Dec 2002 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030105517 | White et al. | Jun 2003 | A1 |
20030114913 | Spenser et al. | Jun 2003 | A1 |
20030120263 | Ouriel et al. | Jun 2003 | A1 |
20030120330 | Ouriel et al. | Jun 2003 | A1 |
20030120333 | Ouriel et al. | Jun 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030176914 | Rabkin et al. | Sep 2003 | A1 |
20030199971 | Tower et al. | Oct 2003 | A1 |
20030220683 | Minasian et al. | Nov 2003 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040087900 | Thompson et al. | May 2004 | A1 |
20040093058 | Cottone et al. | May 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040102842 | Jansen | May 2004 | A1 |
20040117009 | Cali et al. | Jun 2004 | A1 |
20040133273 | Cox | Jul 2004 | A1 |
20040186561 | McGuckin et al. | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040210307 | Khairkhahan | Oct 2004 | A1 |
20040215325 | Penn et al. | Oct 2004 | A1 |
20040225353 | McGuckin et al. | Nov 2004 | A1 |
20040236411 | Sarac et al. | Nov 2004 | A1 |
20040243230 | Navia et al. | Dec 2004 | A1 |
20040249433 | Freitag | Dec 2004 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050038470 | van der Burg et al. | Feb 2005 | A1 |
20050075727 | Wheatley | Apr 2005 | A1 |
20050090887 | Pryor | Apr 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050107872 | Mensah et al. | May 2005 | A1 |
20050119722 | Styrc et al. | Jun 2005 | A1 |
20050125020 | Meade et al. | Jun 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137693 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050137701 | Salahieh et al. | Jun 2005 | A1 |
20050154444 | Quadri | Jul 2005 | A1 |
20050159811 | Lane | Jul 2005 | A1 |
20050182483 | Osborne et al. | Aug 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050203616 | Cribier | Sep 2005 | A1 |
20050216079 | MaCoviak | Sep 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20060020247 | Kagan et al. | Jan 2006 | A1 |
20060020327 | Lashinski et al. | Jan 2006 | A1 |
20060052802 | Sterman et al. | Mar 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060095115 | Bladillah et al. | May 2006 | A1 |
20060106454 | Osborne et al. | May 2006 | A1 |
20060116625 | Renati et al. | Jun 2006 | A1 |
20060129235 | Seguin et al. | Jun 2006 | A1 |
20060149360 | Schwammenthal | Jul 2006 | A1 |
20060161265 | Levine et al. | Jul 2006 | A1 |
20060173537 | Yang et al. | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060212110 | Osborne et al. | Sep 2006 | A1 |
20060224232 | Chobotov | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060259135 | Navia et al. | Nov 2006 | A1 |
20060259136 | Nguyen | Nov 2006 | A1 |
20060265056 | Nguyen | Nov 2006 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20060287719 | Rowe et al. | Dec 2006 | A1 |
20060293745 | Carpentier et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070050021 | Johnson | Mar 2007 | A1 |
20070067016 | Jung | Mar 2007 | A1 |
20070100432 | Case et al. | May 2007 | A1 |
20070118206 | Colgan et al. | May 2007 | A1 |
20070118207 | Amplatz et al. | May 2007 | A1 |
20070123798 | Rahamimov | May 2007 | A1 |
20070129794 | Realyvasquez | Jun 2007 | A1 |
20070142906 | Figulla et al. | Jun 2007 | A1 |
20070162107 | Haug et al. | Jul 2007 | A1 |
20070185559 | Shelso | Aug 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070219620 | Eells et al. | Sep 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070250151 | Pereira | Oct 2007 | A1 |
20070255391 | Hojeibane et al. | Nov 2007 | A1 |
20070255394 | Ryan | Nov 2007 | A1 |
20070270932 | Headley et al. | Nov 2007 | A1 |
20070270937 | Leanna | Nov 2007 | A1 |
20070293940 | Schaeffer et al. | Dec 2007 | A1 |
20080009934 | Schneider et al. | Jan 2008 | A1 |
20080021546 | Patz et al. | Jan 2008 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071363 | Tuval et al. | Mar 2008 | A1 |
20080071369 | Tuval et al. | Mar 2008 | A1 |
20080082164 | Friedman | Apr 2008 | A1 |
20080082165 | Wilson et al. | Apr 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080097571 | Denison et al. | Apr 2008 | A1 |
20080097581 | Shanley | Apr 2008 | A1 |
20080114441 | Rust et al. | May 2008 | A1 |
20080125853 | Bailey et al. | May 2008 | A1 |
20080125859 | Salahieh et al. | May 2008 | A1 |
20080133003 | Seguin et al. | Jun 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147179 | Cai et al. | Jun 2008 | A1 |
20080147183 | Styrc | Jun 2008 | A1 |
20080161911 | Revuelta et al. | Jul 2008 | A1 |
20080177381 | Navia et al. | Jul 2008 | A1 |
20080183273 | Mesana et al. | Jul 2008 | A1 |
20080208307 | Ben-Muvhar et al. | Aug 2008 | A1 |
20080208328 | Antocci et al. | Aug 2008 | A1 |
20080208332 | Lamphere et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20080228254 | Ryan | Sep 2008 | A1 |
20080243233 | Ben-Muvhar et al. | Oct 2008 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080262596 | Xiao | Oct 2008 | A1 |
20080269878 | Tobbi | Oct 2008 | A1 |
20080275549 | Rowe | Nov 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090054976 | Tuval et al. | Feb 2009 | A1 |
20090062908 | Bonhoeffer et al. | Mar 2009 | A1 |
20090076585 | Hendriksen et al. | Mar 2009 | A1 |
20090076598 | Salahieh et al. | Mar 2009 | A1 |
20090082844 | Zacharias et al. | Mar 2009 | A1 |
20090082847 | Zacharias et al. | Mar 2009 | A1 |
20090088832 | Chew et al. | Apr 2009 | A1 |
20090125096 | Chu et al. | May 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090149946 | Dixon | Jun 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090163934 | Raschdorf, Jr. et al. | Jun 2009 | A1 |
20090171438 | Chuter et al. | Jul 2009 | A1 |
20090171456 | Kveen et al. | Jul 2009 | A1 |
20090177262 | Oberti et al. | Jul 2009 | A1 |
20090182407 | Leanna et al. | Jul 2009 | A1 |
20090182413 | Burkart et al. | Jul 2009 | A1 |
20090188964 | Orlov | Jul 2009 | A1 |
20090192601 | Rafiee et al. | Jul 2009 | A1 |
20090216314 | Quadri | Aug 2009 | A1 |
20090234443 | Ottma et al. | Sep 2009 | A1 |
20090248132 | Bloom et al. | Oct 2009 | A1 |
20090248133 | Bloom et al. | Oct 2009 | A1 |
20090264997 | Salahieh et al. | Oct 2009 | A1 |
20090270972 | Lane | Oct 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281618 | Hill et al. | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090287296 | Manasse | Nov 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20090292350 | Eberhardt et al. | Nov 2009 | A1 |
20090306768 | Quadri | Dec 2009 | A1 |
20100004740 | Seguin et al. | Jan 2010 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100036484 | Hariton | Feb 2010 | A1 |
20100082094 | Quadri et al. | Apr 2010 | A1 |
20100094411 | Tuval et al. | Apr 2010 | A1 |
20100114299 | Ben Muvhar et al. | May 2010 | A1 |
20100114305 | Kang et al. | May 2010 | A1 |
20100121461 | Sobrino-Serrano et al. | May 2010 | A1 |
20100161027 | Orr | Jun 2010 | A1 |
20100179633 | Solem | Jul 2010 | A1 |
20100179647 | Carpenter et al. | Jul 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100249909 | McNamara | Sep 2010 | A1 |
20100249911 | Alkhatib | Sep 2010 | A1 |
20100256723 | Murray | Oct 2010 | A1 |
20100262157 | Silver et al. | Oct 2010 | A1 |
20100274345 | Rust | Oct 2010 | A1 |
20100280606 | Naor | Nov 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20100305685 | Millwee et al. | Dec 2010 | A1 |
20100312333 | Navia et al. | Dec 2010 | A1 |
20110004296 | Lutter et al. | Jan 2011 | A1 |
20110004299 | Essinger et al. | Jan 2011 | A1 |
20110022165 | Oba et al. | Jan 2011 | A1 |
20110029067 | McGuckin, Jr. et al. | Feb 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110166644 | Keeble et al. | Jul 2011 | A1 |
20110178597 | Navia et al. | Jul 2011 | A9 |
20110208297 | Tuval et al. | Aug 2011 | A1 |
20110208298 | Tuval et al. | Aug 2011 | A1 |
20110218619 | Benichou et al. | Sep 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110264196 | Savage | Oct 2011 | A1 |
20110313515 | Quadri et al. | Dec 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120041550 | Salahieh et al. | Feb 2012 | A1 |
20120059452 | Boucher et al. | Mar 2012 | A1 |
20120059454 | Millwee et al. | Mar 2012 | A1 |
20120078353 | Quadri et al. | Mar 2012 | A1 |
20120078360 | Rafiee | Mar 2012 | A1 |
20120101571 | Thambar et al. | Apr 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120179239 | Quadri | Jul 2012 | A1 |
20120215303 | Quadri et al. | Aug 2012 | A1 |
20120259405 | Weber et al. | Oct 2012 | A1 |
20120271398 | Essinger et al. | Oct 2012 | A1 |
20120290062 | McNamara et al. | Nov 2012 | A1 |
20120296418 | Bonyuet et al. | Nov 2012 | A1 |
20120303116 | Gorman, III et al. | Nov 2012 | A1 |
20120310328 | Olson et al. | Dec 2012 | A1 |
20120323316 | Chau et al. | Dec 2012 | A1 |
20130006294 | Kashkarov et al. | Jan 2013 | A1 |
20130018458 | Yohanan et al. | Jan 2013 | A1 |
20130053950 | Rowe et al. | Feb 2013 | A1 |
20130110227 | Quadri et al. | May 2013 | A1 |
20130131788 | Quadri et al. | May 2013 | A1 |
20130131793 | Quadri et al. | May 2013 | A1 |
20130138203 | Quadri | May 2013 | A1 |
20130138207 | Quadri et al. | May 2013 | A1 |
20130144375 | Giasolli et al. | Jun 2013 | A1 |
20130144380 | Quadri et al. | Jun 2013 | A1 |
20130144381 | Quadri et al. | Jun 2013 | A1 |
20130150956 | Yohanan et al. | Jun 2013 | A1 |
20130172983 | Clerc et al. | Jul 2013 | A1 |
20130184813 | Quadri et al. | Jul 2013 | A1 |
20130211508 | Lane et al. | Aug 2013 | A1 |
20130253635 | Straubinger et al. | Sep 2013 | A1 |
20130304200 | McLean et al. | Nov 2013 | A1 |
20130310928 | Morriss et al. | Nov 2013 | A1 |
20130345786 | Behan | Dec 2013 | A1 |
20140018912 | Delaloye et al. | Jan 2014 | A1 |
20140039611 | Lane et al. | Feb 2014 | A1 |
20140052237 | Lane et al. | Feb 2014 | A1 |
20140052242 | Revuelta et al. | Feb 2014 | A1 |
20140088685 | Yevzlin et al. | Mar 2014 | A1 |
20140100651 | Kheradvar et al. | Apr 2014 | A1 |
20140100653 | Savage et al. | Apr 2014 | A1 |
20140142694 | Tabor et al. | May 2014 | A1 |
20140163668 | Rafiee | Jun 2014 | A1 |
20140172085 | Quadri et al. | Jun 2014 | A1 |
20140172086 | Quadri et al. | Jun 2014 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140214153 | Ottma et al. | Jul 2014 | A1 |
20140214154 | Nguyen et al. | Jul 2014 | A1 |
20140214155 | Kelley | Jul 2014 | A1 |
20140214160 | Naor | Jul 2014 | A1 |
20140222139 | Nguyen et al. | Aug 2014 | A1 |
20140230515 | Tuval et al. | Aug 2014 | A1 |
20140236288 | Lambrecht et al. | Aug 2014 | A1 |
20140257476 | Montorfano et al. | Sep 2014 | A1 |
20140277402 | Essinger et al. | Sep 2014 | A1 |
20140296973 | Bergheim et al. | Oct 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140309728 | Dehdashtian et al. | Oct 2014 | A1 |
20140309731 | Quadri et al. | Oct 2014 | A1 |
20140309732 | Solem | Oct 2014 | A1 |
20140324160 | Benichou et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140336754 | Gurskis et al. | Nov 2014 | A1 |
20140343671 | Yohanan et al. | Nov 2014 | A1 |
20140350666 | Righini | Nov 2014 | A1 |
20140358221 | Ho et al. | Dec 2014 | A1 |
20140364943 | Conklin | Dec 2014 | A1 |
20140371845 | Tuval et al. | Dec 2014 | A1 |
20140371847 | Madrid et al. | Dec 2014 | A1 |
20140371848 | Murray, III et al. | Dec 2014 | A1 |
20140379067 | Nguyen et al. | Dec 2014 | A1 |
20140379068 | Thielen et al. | Dec 2014 | A1 |
20140379077 | Tuval et al. | Dec 2014 | A1 |
20150005873 | Chang et al. | Jan 2015 | A1 |
20150012085 | Salahieh et al. | Jan 2015 | A1 |
20150018938 | Von Segesser et al. | Jan 2015 | A1 |
20150032153 | Quadri et al. | Jan 2015 | A1 |
20150066140 | Quadri et al. | Mar 2015 | A1 |
20150081009 | Quadri et al. | Mar 2015 | A1 |
20150148731 | Mcnamara et al. | May 2015 | A1 |
20150157458 | Thambar et al. | Jun 2015 | A1 |
20150238315 | Rabito et al. | Aug 2015 | A1 |
Number | Date | Country |
---|---|---|
2304325 | Oct 2000 | CA |
2827556 | Jul 2012 | CA |
3128704 | Feb 1983 | DE |
102006052564 | Dec 2007 | DE |
0657147 | Jun 1995 | EP |
1255510 | Nov 2002 | EP |
1472996 | Nov 2004 | EP |
2777617 | Sep 2014 | EP |
1264471 | Feb 1972 | GB |
1315844 | May 1973 | GB |
2245495 | Jan 1992 | GB |
2398245 | Aug 2004 | GB |
2002540889 | Dec 2002 | JP |
2008541865 | Nov 2008 | JP |
9749355 | Dec 1997 | WO |
0053104 | Sep 2000 | WO |
0061034 | Oct 2000 | WO |
0135861 | May 2001 | WO |
0135870 | May 2001 | WO |
0172239 | Oct 2001 | WO |
03011195 | Feb 2003 | WO |
03028522 | Apr 2003 | WO |
03092554 | Nov 2003 | WO |
2004014257 | Feb 2004 | WO |
2004014474 | Feb 2004 | WO |
2004058097 | Jul 2004 | WO |
2005011534 | Feb 2005 | WO |
2005041810 | May 2005 | WO |
2005087140 | Sep 2005 | WO |
2006070372 | Jul 2006 | WO |
2006085304 | Aug 2006 | WO |
2006089236 | Aug 2006 | WO |
2006127765 | Nov 2006 | WO |
2007025028 | Mar 2007 | WO |
2007034488 | Mar 2007 | WO |
2007058857 | May 2007 | WO |
2007123658 | Nov 2007 | WO |
2007134290 | Nov 2007 | WO |
2008005535 | Jan 2008 | WO |
2008013915 | Jan 2008 | WO |
2008070797 | Jun 2008 | WO |
2008091515 | Jul 2008 | WO |
2008103722 | Aug 2008 | WO |
2008150529 | Dec 2008 | WO |
2009026563 | Feb 2009 | WO |
2009033469 | Mar 2009 | WO |
2009045331 | Apr 2009 | WO |
2009052188 | Apr 2009 | WO |
2009053497 | Apr 2009 | WO |
2009094500 | Jul 2009 | WO |
2009134701 | Nov 2009 | WO |
2009137359 | Nov 2009 | WO |
2009149462 | Dec 2009 | WO |
2009155561 | Dec 2009 | WO |
2010008549 | Jan 2010 | WO |
2010037141 | Apr 2010 | WO |
2010040009 | Apr 2010 | WO |
2010057262 | May 2010 | WO |
2010098857 | Sep 2010 | WO |
2010138853 | Dec 2010 | WO |
2011025945 | Mar 2011 | WO |
2011109801 | Sep 2011 | WO |
2011109813 | Sep 2011 | WO |
2011137531 | Nov 2011 | WO |
2012035279 | Mar 2012 | WO |
2012162228 | Nov 2012 | WO |
2012177942 | Dec 2012 | WO |
2013012801 | Jan 2013 | WO |
2013028387 | Feb 2013 | WO |
2013086413 | Jun 2013 | WO |
Entry |
---|
Bavaria, Joseph E. M.D. et al.: “Transcatheter Mitral Valve Implantation: The Future Gold Standard for MR?,” Applicant requests the Examiner to consider this reference to be prior art as of Dec. 2010. |
Bavaria, Joseph E. M.D.: “CardiAQ Valve Technologies: Transcatheter Mitral Valve Implantation,” Sep. 21, 2009. |
Businesswire.com, CardiAQ Valve Technologies, “CardiAQ Valve Technologies (“CVT”) to disclose data during ‘EuroPCR 2010’ about the world's first successful in vivo transcatheter delivery of a mitral heart valve implant,” Irvine, California, May 20, 2010. |
Businesswire.com, “CardiAQ Valve Technologies (CVT) Discloses Successful Results of Acute In Vivo Study of Its Novel Transcatheter Mitral Valve Implantation (TMVI) System,” Sep. 28, 2009. |
Berreklouw, Eric, MD, PhD, et al., “Sutureless Mitral Valve Replacement With Bioprostheses and Nitinol Attachment Rings: Feasibility in Acute Pig Experiments,” The Journal of Thoracic and Cardiovascular Surgery, vol. 142, No. 2, Aug. 2011 in 7pages, Applicant believes this may have been available online as early as Feb. 4, 2011. |
Boudjemline, Younes, MD, et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves,” JACC, vol. 46, No. 2, Jul. 19, 2005:360-5. |
Brinkman, William T., MD, et al., Transcatheter Cardiac Valve Interventions, Surg Clin N Am 89 (2009) 951-966, Applicant believes this may have been available as early as Aug. 2009. |
CardiAQ Valve Technologies, “Innovations in Heart Valve Therapy,” In3 San Francisco, Jun. 18, 2008, PowerPoint presentation in 19 slides. |
CardiAQ Valve Technologies Company Fact Sheet 2009. |
Chiam, Paul T.L., et al., “Percutaneous Transcatheter Aortic Valve Implantation: Assessing Results, Judging Outcomes, and Planning Trials,” JACC: Cardiovascular Interventions, The American College of Cardiology Foundation, vol. 1, No. 4, Aug. 2008:341-50. |
“Company Overview,” Jun. 25, 2009 at TVT. |
Condado, Jose Antonio, et al., “Percutaneous Treatment of Heart Valves,” Rev Esp Cardio. 2006;59(12):1225-31, Applicant believes this may have been available as early as Dec. 2006. |
Feldman, Ted, MD. “Prospects for Percutaneous Valve Therapies,” Circulation 2007;116:2866-2877. Applicant believes that this may be available as early as Dec. 11, 2007. |
Fitzgerald, Peter J. M.D., “Tomorrow's Technology: Percutaneous Mitral Valve Replacement, Chordal Shortening, and Beyond,” Transcatheter Valve Therapies (TVT) Conference. Seattle, WA. Applicant believes this may have been available as early as Jun.7, 2010. |
Grube, Eberhard, MD, et al., “Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease, The Siegburg First-in-Man Study” Journal of the American Heart Association, 2006;114:1616-1624, originally published online Oct. 2, 2006. |
Grube, E. et al., “Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.” J Am CollCardiol. Jul. 3, 2007;50(1):69-76. Epub Jun. 6, 2007. |
Horvath et al.: “Transapical Aortic Valve Replacement under Real-time Magnetic Resonance Imaging Guidance: Experimental Results with Balloon-Expandable and Self-Expanding Stents,” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038190/. Jun. 2011. |
JenaValve Technology, “The JenaValve—The Prosthesis”, 2011 JenaValve Technology in 1 page. |
Karimi, Houshang, MD, et al., “Percutaneous Valve Therapies,” SIS 2007 Yearbook, Chapter 11, pp. 1-11. |
Kronemyer, Bob: “CardiAQ Valve Technologies: Percutaneous Mitral Valve Replacement,” Start Up-Windhover Review of Emerging Medical Ventures, vol. 14, Issue No. 6, Jun. 2009, pp. 48-49. |
Lauten, Alexander, et al., “Experimental Evaluation of the JenaClip Transcatheter Aortic Valve,” Catheterization and Cardiovascular Interventions 74:514-519, published online May 11, 2009, Applicant believes this may have been available online asearly as Apr. 27, 2009. |
Leon, Martin B., MD, et al., “Transcatheter Aortic Valve Replacement in Patients with Critical Aortic Stenosis: Rationale, Device Descriptions, Early Clinical Experiences, and Perspectives,” Semin. Thorac. Cardiovasc. Surg. 18:165-174, 2006 in 10pages, Applicant believes this may have been available as early as the Summer of 2006. |
Lozonschi, Lucian, MD, et al., “Transapical Mitral Valved Stent Implantation,” Ann Thorac Surg 2008;86:745-8 in 4 pages, Applicant believes this may have been available as early as Sep. 2008. |
Lutter, Georg, et al., “Off-Pump Transapical Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 36 (2009) 124-128, Applicant believes this may have been available as early as Apr. 25, 2009. |
Ma, Liang, et al., “Double-Crowned Valved Stents for Off-Pump Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 28 (2005) 194-199, Applicant believes this may have been available as early as Aug. 2005. |
Mack, Michael M.D., “Advantages and Limitations of Surgical Mitral Valve Replacement; Lessons for the Transcatheter Approach,” Applicant believes this may have been available as early as Jun. 7, 2010. Applicant believes this may have been presentedat the Texas Cardiovascular Innovative Ventures (TCIV) Conference in Dallas, TX on Dec. 8, 2010. |
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: On-Going Experience in Swine Model,” Applicant believes this may have been presented on Nov. 2011 at TCT. |
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: A Short-term Experience in Swine Model,” Applicant believes this may have been presented on May 2011 at TVT. |
Masson, Jean-Bernard, et al., “Percutaneous Treatment of Mitral Regurgitation,” Circulation: Cardiovascular Interventions, 2:140-146, Applicant believes this may have been available as early as Apr. 14, 2009. |
Neovasc corporate presentation, Oct. 2009, available at http://www.neovasc.com/investors/documents/Neovasc-Corporate-Presentation—Oct. 2009.pdf. |
Ostrovsky, Gene, “A Trial of Zenith Fenestrated AAA Endovascular Graft Goes on,” medGadget, Aug. 1, 2008, available at: :http://www.medgadget.com/2008/08/a.sub.-trial.sub.-of.sub.-zenith.sub-.-fenestrated.sub.-aaa.sub.-endovascular.sub.-graft.sub.-goes.sub.-o- n.html. |
Ostrovsky, Gene: “Transcatheter Mitral Valve Implantation Technology from CardiAQ,” medGadget, Jan. 15, 2010, available at: http://www.medgadget.com/2010/01/transcatheter.sub.-mitral.sub.-valve.s-ub.-implantation.sub.-technology.sub.-from.sub.-cardiaq.html. |
Pluth, James R., M.D., et al., “Aortic and Mitral Valve Replacement with Cloth-Covered Braunwald-Cutter Prosthesis, A Three-Year Follow-up,” The Annals of Thoracic Surgery, vol. 20, No. 3, Sep. 1975, pp. 239-248. |
Quadri, Arshad M.D., “Transcatheter Mitral Valve Implantation (TMVI) (An Acute In Vivo Study),” Applicant believes this may have been presented on Sep. 22, 2010 at TCT. |
Ratz, J. Brent, “In3 Company Overview,” Jun. 24, 2009. |
Ratz, J. Brent, “LSI EMT Spotlight,” May 15, 2009. |
Piazza, Nicolo, MD, et al., “Anatomy of the Aortic Valvar Complex and Its Implications for Transcatheter Implantation of the Aortic Valve,” Contemporary Reviews in Interventional Cardiology, Circ. Cardiovasc. Intervent., 2008;1:74-81, Applicantbelieves this may have been available as early as Aug. 2008. |
Ratz, J. Brent et al., “Any experiences making an expandable stent frame?” Arch-Pub.com, Architecture Forums: Modeling, Multiple forum postings from Feb. 3, 2009 to Feb. 4, 2009, http://www.arch-pub.com. |
Ratz, J. Brent et al., “Fabric, Skin, Cloth expansion . . . best approach?,” Area by Autodesk, 3ds Max: Modeling, Forum postings from Feb. 18, 2009 to Feb. 19, 2009, http://area.autodesk.com. |
Ratz, J. Brent et al., “Isolating Interpolation,” Arch-Pub.com, Architecture Forums: Animation and Rigging, Forum postings from Feb. 9, 2009 to Feb. 10, 2009, http://www.arch-pub.com. |
Ruiz, Carlos E., “Overview of Novel Transcatheter Valve Technologies,” Applicant believes this may have been presented on May 27, 2010 at EuroPCR. |
Spillner, J. et al., “New Sutureless ‘Atrial-Mitral-Valve Prosthesis’ for Minimally Invasive Mitral Valve Therapy,” Textile Research Journal, 2010, in 7 pages, Applicant believes this may have been available as early as Aug. 9, 2010. cited byapplicant. |
Seidel, Wolfgang, et al., “A Mitral Valve Prosthesis and a Study of Thrombosis on Heart Valves in Dogs,” JSR—vol. II, No. 3—May 1962, submitted for publication Oct. 9, 1961. |
“Update,” believed to be presented on Jun. 6, 2010 Applicant believes this may have been presented on Jun. 6, 2010 at TVT. |
Vu, Duc-Thang, MD, et al., “Novel Sutureless Mitral Valve Implantation Method Involving a Bayonet Insertion and Release Mechanism: A Proof of Concept Study in Pigs,” The Journal of Thoracic and Cardiovascular Surgery, vol. 143, No. 4, 985-988, Apr. 2012, Applicant believes this may have been available online as early as Feb. 11, 2012. |
Van Mieghem, et al., “Anatomy of the Mitral Valvular Complez and Its Implications for Transcatheter Interventions for Mitral Regurgitation,” J. Am. Coll. Cardiol., 56:617-626 (Aug. 17, 2010). |
Walther, Thomas et al., “Transapical Approach for Sutureless Stent-Fixed Aortic Valve Implantation: Experimental Results,” European Journal of Cardio-thoracic Surgery 29 (2006) 703-708, Applicant believes this may have been available as early as May 2006. |
Wayback Machine, Neovasc Ostial Products Overview, https://web.archive.org/web/20090930050359/https://www.neovasc.com/vascul- ar-products/ostialproducts/default.php, indicated as archived on Sep. 30, 2008. |
Webb, John G., et al., Transcatheter Aortic Valve Implantation: The Evolution of Prostheses, Delivery Systems and Approaches, Archives of Cardiovascular Disease (2012) 105, 153-159, Applicant believes this may have been available as early as Mar. 16, 2012. |
Number | Date | Country | |
---|---|---|---|
20200360136 A1 | Nov 2020 | US |
Number | Date | Country | |
---|---|---|---|
61445963 | Feb 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15011247 | Jan 2016 | US |
Child | 16227401 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16227401 | Dec 2018 | US |
Child | 16941232 | US | |
Parent | 13755406 | Jan 2013 | US |
Child | 15011247 | US | |
Parent | 13403929 | Feb 2012 | US |
Child | 13755406 | US |